Pharmafile Logo

ACT therapy

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

It is estimated there will be around 66,000 new cases of uterine cancer in the US this year

- PMLiVE

FDA proposes improvements for oncology clinical trials supporting accelerated approval

The draft guidance discusses the advantage of randomised clinical trials over single-arm studies

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

- PMLiVE

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

The disease develops in the lungs and accounts for 75% of all cancerous mesothelioma cases

- PMLiVE

Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients

The decision removes the previous 20% Ki-67 score requirement for patient selection

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

- PMLiVE

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

- PMLiVE

MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

- PMLiVE

ICR discovery could lead to new series of cancer drugs

The team found new inhibitors that block the action of a cancer-driving protein

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links